SUBSCRIBE
IQVIA Blog Digest
For all the latest industry insights, please subscribe to the IQVIA U.S. blog digest.
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
WHO WE HELP
-
Pharmaceutical Manufacturers
-
Emerging Biopharma
-
MedTech
-
Financial Institutions
-
Government and Public Health
-
Health Plans
-
Hospital and Health Systems
-
Insurers and Risk
-
Medical Specialty and Patient Advocacy
Pharmaceutical Manufacturers
Harness unparalleled healthcare data, advanced analytics, and cutting-edge technologies with our expertise to accelerate the development and commercialization of innovative medicines, enhancing patient lives.
Discover MorePharmaceutical Manufacturers
Emerging Biopharma (Global page)
Boost your innovation with IQVIA's expert team. Our comprehensive solutions integrate top-tier insights, technology, and expertise to maximize your asset's success in a competitive landscape.
Discover InnovationsMedTech
Navigating MedTech's unique landscape: U.S. decision-making now rests with GPOs, IDNs, and payers, who demand solid value proof through rigorous outcomes analyses and pricing scrutiny.
Explore MedTechMedTech
Financial Institutions
Invest in healthcare with confidence. Stay ahead of pharma and medical device trends using real-time, high-quality data. Access market insights, historical sales, prescription trends, and emerging product information for informed, risk-reduced decisions.
Access InsightsGovernment and Public Health
Unlock deeper health insights with unmatched data and innovative technology to enhance decision-making for your essential government programs.
Unlock InnovationsGovernment and Public Health
Health Plans
Accelerate digital innovation with our data-driven expertise in data science and healthcare, optimizing business processes for smarter decisions.
Navigate Health PlansHospital and Health Systems
Leverage digital innovation to cut costs, boost efficiency, and elevate patient engagement, all while enhancing quality and health outcomes.
Streamline DecisionsHospital and Health Systems
Insurers and Risk
Enhance your ability to evaluate and forecast population risk swiftly and accurately by integrating unmatched data, expertise, and technology.
Uncover More
Medical Specialty and Patient Advocacy
Transform into a data-driven organization that enhances your specialty and showcases value to your members through digital transformation.
Explore NowU.S. PROGRESS POINT
A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREBLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTS
PODCASTS
"Discover the future through our enlightening podcasts available in the United States.
EXPLORE PODCASTSBlog
Enabling MSLs: Three Paths to Better Engagement, Greater Value
Sep 20, 2021
Before the pandemic, medical science liaisons (MSLs) had plenty of opportunities to get to know thought leaders (TLs). Even a brief conversation could yield insights into a thought leader’s practice and priorities. Whether during a conference or outside office hours, lengthier discussions provided even more value in helping MSLs build knowledge and strengthen relationships.
In the face of COVID-19 shutdowns, MSLs had to shift quickly from in-person interactions to virtual sessions with TLs. They rose to the challenge admirably, and their adaptability and resiliency deserve kudos. But as the industry continues navigating a “new normal,” MSLs need more than gratitude; they need a higher level of enablement to succeed with largely digital engagement.
Some TL relationships are well established. For those, MSLs can supplement formal video conferencing meetings with sidebar conversations to understand providers’ needs and preferences. To nurture nascent relationships, MSLs need other ways to gather and digest detailed information. They need help understanding which aspects of the scientific story are most likely to resonate for each TL. They need support in connecting each provider’s preferences and priorities to the available scientific and medical affairs resources.
The good news? Even as ongoing restrictions reduce everyone’s time and ability to engage face to face, TLs see tremendous value in their relationships with MSLs. To maximize that value, medical affairs teams can start rethinking deployment strategies – including how strategic and tactical context is delivered to MSL teams.
These three investments are great places to start:
- Develop TL “dossiers.” While customer relationship management systems store important provider and practice details, they often fall short in properly preparing MSLs for their interactions with TLs. MSLs need to know more than basic demographics; they need insights into a TL’s research interests and history, including the most recent publications.
With these details, MSLs can better anticipate the mindset and experience a TL brings to their discussions. That, in turn, helps MSLs tailor what they share and how they share it. It also prepares them to understand more about the “why” that shapes a TL’s point of view. - Illuminate TL networks. Providers practice as part of formal and informal networks that continually share information and act as trusted advisors to each other. Often these networks include TLs who are highly influential yet “hidden” when compared to the most prominent voices.
With access to comprehensive TL maps, MSLs can better understand how each TL fits within a local or regional network. These insights help in crafting more tailored messages and conducting more effective conversations.
What’s more, MSLs can tap into these networks as indirect yet effective channels for conveying scientific messages to hard-to-reach providers. That has become more important in the face of pandemic-related restrictions and added constraints on the healthcare system. These factors have reduced some providers’ access to their networks, positioning MSLs as even more sought-after conduits of scientific information. - Link strategy and science. Making an abundance of scientific and medical affairs resources available to MSLs is good. What’s better is distilling the information and being clear about how it aligns with the strategic mission, vision, and objectives. With that additional context, MSLs can be more precise about which resource to use, with whom, and when.
Above all, remember that providers overwhelmingly want to engage with MSLs, and they value the scientific knowledge and expertise that MSLs bring to the table. When enabled with greater context, MSLs can focus where they bring the most value: building and strengthening relationships with thought leaders; telling personalized, compelling scientific stories; and providing medical insights for the organization.
IQVIA Medical Affairs
Leverage the therapeutic expertise and commercial acumen needed to demonstrate and communicate the value of your therapy more effectively and efficiently.